Natco Pharma was promoted by V C Nannapaneni in the year 1981 as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh. The company focus is primarily on niche therapeutic areas and complex products. It market and distribute products in various countries. It also operates in certain key geographies through its subsidiaries.

Natco Pharma manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.

Business area of the company

Natco Pharma is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). It is also engaged in contract manufacturing business, whereby it undertake selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.

Natco Pharma Ltd.

Alembic Pharmaceuticals Ltd.

Eris Lifesciences Ltd.

Astrazeneca Pharma India Ltd.

Suven Pharmaceuticals Ltd.

Pfizer Ltd.

Granules India Ltd.

Caplin Point Laboratories Ltd.

Sanofi India Ltd.

Medplus Health Services Ltd.

Procter & Gamble Health Ltd.

Glenmark Life Sciences Ltd.

Jubilant Pharmova Ltd.

Piramal Enterprises Ltd.

Marksans Pharma Ltd.

Market Cap	14,020 Cr	ROE	15.7%
P/E Ratio(TTM)	12.4	EPS(TTM)	0.0
P/B Ratio	2.6	Dividend Yield	0.7%
Industry P/E	40.3	Book Value	295.5
		Face Value	2.0

Fundamentals